Outcome MeasureQuality of Life

SF-36

36-Item Short Form Health Survey

3 Papers in Blossom

About This Instrument

The 36-Item Short Form Health Survey (SF-36) is one of the most widely used generic health-related quality of life instruments. Developed by John Ware at RAND, it measures eight health domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. Scores for each domain range from 0 to 100, with higher scores indicating better health. Two summary scores can be derived: the Physical Component Summary (PCS) and Mental Component Summary (MCS). In psychedelic research, the SF-36 serves as a secondary endpoint to assess whether symptom-specific improvements (e.g., depression, PTSD) translate into broader health-related quality of life gains. It enables comparison of treatment effects across different conditions and interventions and is recognized by regulatory agencies as a patient-reported outcome measure.

Outcome Data Across Studies

Reported results for SF-36 across 1 study with quantitative data.

Outcome data across 6 study arm–timepoint observations
SD
MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up
2025Secondary
MDMA-assisted psychotherapy(experimental)0————
MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up
2025Secondary
MDMA-assisted psychotherapy(experimental)011—25.6—
MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up
2025Secondary
MDMA-assisted psychotherapy(experimental)01176.425.6—
MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up
2025Secondary
MDMA-assisted psychotherapy(experimental)90————
MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up
2025Secondary
MDMA-assisted psychotherapy(experimental)9011—28.9—
MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up
2025Secondary
MDMA-assisted psychotherapy(experimental)901177.228.9—

Papers Using SF-36

Open Accessindividual

Pilot study of psilocybin in patients with post-treatment lyme disease

In an open‑label, single‑arm pilot study of 20 patients with post‑treatment Lyme disease, two psilocybin sessions with psychological support produced significant, sustained reductions in symptom burden (40% decrease in GSQ‑30 at six months) and improvements in both physical and mental quality of life. The intervention was feasible and well-tolerated with no serious related adverse events, supporting further controlled trials of psilocybin‑assisted therapy for PTLD.

Published
Journal
Scientific Reports
Authors
Garcia-Romeu, A., Naudé, G. P., Rebman, A. W., So, S., Yaffe, A., Geithner, I., Kozero, E. A., Yang, T., Soloski, M. J., Aucott, J. N.
Open Accessindividual

MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up

In an open‑label feasibility study of 14 recently detoxified participants, Bayesian analysis estimated a 55–63% probability that MDMA‑assisted psychotherapy produced a two‑level reduction in WHO drinking‑risk at 3‑month follow‑up, with preliminary reductions in alcohol craving and improvements in sleep and psychosocial functioning. The paper frames a harm‑reduction endpoint for AUD and provides early evidence that MDMA‑assisted psychotherapy may improve quality of life alongside reduced drinking.

Published
Journal
Alcohol and Alcoholism
Authors
Thurgur, H., Sessa, B., Higbed, L., O'brien, S., Durant, C., Wilson, S., Szigeti, B., Morgan, C. J. A., Nutt, D. J.
Open Accessindividual

Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial

This double-blind, placebo-controlled study (n=30) explores oxytocin deficiency in patients with arginine vasopressin deficiency (central diabetes insipidus), using MDMA as a biochemical and psychoactive provocation test. The participants included patients with vasopressin deficiency and healthy controls, who were given either MDMA or placebo in a randomised order over two sessions.

Published
Journal
Lancet Diabetes Endocrinol
Authors
Atila, C., Christ-Crain, M., Liechti, M. E., Holze, F., Murugesu, R., Phd, R., Hutter, N., Sailer, C. O., Heinrichs, M., Rommers, N., Varghese, N., Eckert, A.

Quick Facts

Full Name
36-Item Short Form Health Survey
Domain
Quality of Life
Papers Indexed
3
Score Range
0–100
Interpretation
Higher = better
Unit
points
All Measures